Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (540)	6/12/2003 12:37:02 AM
From: scaram(o)uche	Respond to of 1022

Chromatin Appoints Dr. Mich Hein as President and CEO CHICAGO, Jan. 7 /PRNewswire/ -- Chromatin, Inc. today announced that its Board of Directors has appointed Dr. Mich Hein as President and CEO effective January 1, 2003. Prior to assuming his position with Chromatin, Dr. Hein founded Epicyte Pharmaceuticals (San Diego, California) where he served as Director and President for six years. "The Board and Founders of Chromatin are extremely pleased to have attracted someone of Mich's caliber to lead the development of Chromatin's exciting mini-chromosome technology," said Roger Wyse, Chairman of the Board of Chromatin. "Mich brings a unique combination of scientific knowledge, experience in leading a start up company, understanding of the market dynamics at the interface of agriculture, pharmaceuticals and industrial biotechnology as well as fundraising acumen. His track record in commercializing plant biotechnology is outstanding," added Wyse. Dr. Hein brings to Chromatin extensive business and relevant scientific experience as well as considerable scientific expertise in analytical chemistry, plant molecular biology, and immunology. At Epicyte, he managed the company's strategic business development, government relations and key commercial alliances, including relationships with the Dow Chemical Company and DowAgroSciences, Biovation, and the Centocor division of J&J. Dr. Hein also directed Epicyte's research and development programs funded through DARPA, USAMRIID, and the NIH. Dr. Hein began his career as a research chemist at Monsanto, and subsequently managed the plant molecular biology research effort for PPG Industries in La Jolla, CA. He left PPG to join the faculty of the Departments of Cell Biology and Molecular Biology at The Scripps Research Institute. In addition to his business experience, he is a pioneer in the development of plants for production of antibodies, vaccine subunits and other high value proteins -- an area in which he is an inventor on numerous patents. Chromatin, Inc. is headquartered in Chicago, IL and was founded in 2000, based on technology developed in the laboratory of Dr. Daphne Preuss and her colleagues at the University of Chicago. Chromatin's mini-chromosome technology is designed to significantly accelerate the pace of crop improvement, enabling the rapid delivery of large numbers of genes. The company's suite of intellectual property enables the development of crops with improved genetics to enhance nutritional value, and food safety, and can accelerate the discovery and development of affordable pharmaceuticals and production of industrial and consumer products. (might be worth watching..... Dr. Hein, a good friend, knows the routes -- if they exist -- around any Epicyte patents.)

To: scaram(o)uche who wrote (540)	6/12/2003 4:21:09 AM
From: nigel bates	Read Replies (1) \| Respond to of 1022

As far as I can see, the LSBC method doesn't infringe. the Epicyte patent covers nucleotide sequences inserted into the plant genome. LSBC are using a tobacco mosaic virus. Aren't the two things different ? .United States Patent 5,977,438 Turpen , et al. November 2, 1999 ------------------------------------------------------------------------ Production of peptides in plants as viral coat protein fusions Abstract The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have many uses. Such uses include use as antigens for inducing the production of antibodies having desired binding properties, e.g., protective antibodies, or for use as vaccine antigens for the induction of protective immunity, including immunity against parasitic infections. ------------------------------------------------------------------------ Inventors: Turpen; Thomas H. (Vacaville, CA); Reinl; Stephen J. (Sacramento, CA); Grill; Laurence K. (Vacaville, CA) Assignee: Biosource Technologies, Inc. (Vacaville, CA) Appl. No.: 324003 Filed: October 14, 1994